Minneapolis VA Center for Care Delivery and Outcomes Research, Minneapolis, MN, USA; Section of General Medicine, University of Minnesota School of Medicine, Minneapolis MN, USA.
University of Minnesota School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Eur Urol. 2020 Jun;77(6):713-724. doi: 10.1016/j.eururo.2020.02.009. Epub 2020 Feb 21.
Very long-term mortality in men with early prostate cancer treated with surgery versus observation is uncertain.
To determine long-term effects of surgery versus observation on all-cause mortality for men with early prostate cancer.
DESIGN, SETTING, AND PARTICIPANTS: This study evaluated long-term follow-up of a randomized trial conducted at the US Department of Veterans Affairs and National Cancer Institute sites. The participants were men (n=731) ≤75yr of age with localized prostate cancer, prostate-specific antigen (PSA) <50ng/ml, life expectancy ≥10yr, and medically fit for surgery.
Radical prostatectomy versus observation.
All-cause mortality was assessed in the entire cohort and patient and tumor subgroups. Intention-to-treat analysis was conducted using Kaplan-Meier methods with log-rank tests and Cox proportional hazard models; cumulative mortality incidence, between-group differences, and relative risks were also assessed at predefined time periods.
During 22.1yr (median follow-up for survivors=18.6yr; interquartile range: 16.6-20.0), 515 men died; 246 of 346 men (68%) were assigned to surgery versus 269 of 367 (73%) assigned to observation (hazard ratio 0.84 [95% confidence interval {CI}: 0.70-1.00]; p= 0.044 [absolute risk reduction = 5.7 percentage points, 95% CI: -0.89 to 12%]; relative risk: 0.92 [95% CI: 0.84-1.01]). The restricted mean survival in the surgical group was 13.6 yr (95% CI: 12.9-14.3) versus 12.6 yr (95% CI: 11.8-13.3) in the observation group; a mean of 1 life-year was gained with surgery. Results did not significantly vary by patient or tumor characteristics, although differences were larger favoring surgery among men aged <65 yr, of white race, and having better health status, fewer comorbidities, ≥34% positive prostate biopsy cores, and intermediate-risk disease. Results were not adjusted for multiple comparisons, and we could not assess outcomes other than all-cause mortality.
Surgery was associated with small very long-term reductions in all-cause mortality and increases in years of life gained. Absolute effects did not vary markedly by patient characteristics. Absolute effects and mean survival were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease.
In this randomized study, we evaluated death from any cause in men with early prostate cancer treated with either surgery or observation. Overall, surgery may provide small very long-term reductions in death from any cause and increases in years of life gained. Absolute effects were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease. Strategies are needed to identify men needing and benefitting from surgery while reducing ineffective treatment and overtreatment.
接受手术与观察治疗的早期前列腺癌男性患者的极长期死亡率尚不确定。
确定手术与观察治疗对早期前列腺癌男性全因死亡率的长期影响。
设计、地点和参与者:本研究评估了在美国退伍军人事务部和美国国家癌症研究所进行的一项随机试验的长期随访结果。参与者为年龄≤75 岁、局限性前列腺癌、前列腺特异性抗原(PSA)<50ng/ml、预期寿命≥10 年且适合手术的男性(n=731)。
根治性前列腺切除术与观察治疗。
在整个队列以及患者和肿瘤亚组中评估了全因死亡率。采用 Kaplan-Meier 方法和对数秩检验及 Cox 比例风险模型进行意向治疗分析;还在预先设定的时间间隔评估了累积死亡率、组间差异和相对风险。
在 22.1 年(幸存者的中位随访时间为 18.6 年;四分位间距:16.6-20.0)中,515 名男性死亡;346 名男性中有 246 名(68%)被分配到手术组,367 名男性中有 269 名(73%)被分配到观察组(风险比 0.84 [95%置信区间:0.70-1.00];p=0.044 [绝对风险降低=5.7 个百分点,95%置信区间:-0.89 至 12%];相对风险:0.92 [95%置信区间:0.84-1.01])。手术组的限制性平均生存时间为 13.6 年(95%置信区间:12.9-14.3),观察组为 12.6 年(95%置信区间:11.8-13.3);手术组平均增加了 1 年的生存时间。尽管在年龄<65 岁、白种人、健康状况更好、合并症更少、前列腺活检阳性核心≥34%和中危疾病的男性中,手术的获益更大,但结果并未因患者特征而显著改变。结果未经过多次比较校正,我们也无法评估除全因死亡率以外的其他结局。
手术与全因死亡率的微小长期降低和生存年数的增加相关。绝对效果在患者特征方面差异不显著。在低危疾病男性中,绝对效果和平均生存时间较小,但在中危疾病男性中更大,尽管高危疾病男性中并非如此。
在这项随机研究中,我们评估了接受手术或观察治疗的早期前列腺癌男性的任何原因导致的死亡。总体而言,手术可能会降低全因死亡率,并增加生存年数。在低危疾病男性中,绝对效果较小,但在中危疾病男性中更大,尽管高危疾病男性中并非如此。需要制定策略来确定需要并受益于手术的男性,同时减少无效治疗和过度治疗。